NICE guidance on pazopanib for first-line treatment of advanced renal-cell carcinoma

被引：4
|
作者：
Griffiths, Christian [1 ]
Hay, Nicola [1 ]
Sutcliffe, Frances [1 ]
Stevens, Andrew [1 ]
机构：
[1] Natl Inst Hlth & Clin Excellence, Manchester, Lancs, England
来源：
LANCET ONCOLOGY | 2011年 / 12卷 / 03期
关键词：
INTERFERON ALPHA-2A; RANDOMIZED-TRIAL; MEDROXYPROGESTERONE; VINBLASTINE;
D O I：
10.1016/S1470-2045(11)70042-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：221 / 222
页数：2
相关论文
共 50 条
  • [1] Pazopanib for the First-Line Treatment of Patients with Advanced and/or Metastatic Renal Cell Carcinoma A NICE Single Technology Appraisal
    Kilonzo, Mary
    Hislop, Jenni
    Elders, Andrew
    Fraser, Cynthia
    Bissett, Donald
    McClinton, Samuel
    Mowatt, Graham
    Vale, Luke
    PHARMACOECONOMICS, 2013, 31 (01) : 15 - 24
  • [2] Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain
    Guillermo Villa
    Luis-Javier Hernández-Pastor
    BMC Cancer, 13
  • [3] Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain
    Villa, Guillermo
    Hernandez-Pastor, Luis-Javier
    BMC CANCER, 2013, 13
  • [4] Pazopanib for the First-Line Treatment of Patients with Advanced and/or Metastatic Renal Cell CarcinomaA NICE Single Technology Appraisal
    Mary Kilonzo
    Jenni Hislop
    Andrew Elders
    Cynthia Fraser
    Donald Bissett
    Samuel McClinton
    Graham Mowatt
    Luke Vale
    PharmacoEconomics, 2013, 31 : 15 - 24
  • [5] Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma
    Bianconi, Maristella
    Faloppi, Luca
    Loretelli, Cristian
    Zizzi, Antonio
    Giampieri, Riccardo
    Bittoni, Alessandro
    Andrikou, Kalliopi
    Del Prete, Michela
    Burattini, Luciano
    Montironi, Rodolfo
    Scartozzi, Mario
    Cascinu, Stefano
    ONCOTARGET, 2016, 7 (25) : 37599 - 37607
  • [6] Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma
    Labriola, Matthew K.
    Batich, Kristen A.
    Zhu, Jason
    McNamara, Megan A.
    Harrison, Michael R.
    Armstrong, Andrew J.
    George, Daniel J.
    Zhang, Tian
    CLINICAL GENITOURINARY CANCER, 2019, 17 (03) : E513 - E521
  • [7] Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma
    Escudier, Bernard
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (12): : 1176 - 1178
  • [8] Economic evaluation of pazopanib as first-line treatment of metastatic renal cell carcinoma in Greece
    Solakidi, A.
    Kourlaba, G.
    Kontovinis, L.
    Bournakis, E.
    Boutis, A.
    Koutsoukos, K.
    Syrios, J.
    Tzovaras, A.
    Chatzikou, M.
    Michailidi, C.
    Maniadakis, N.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Pazopanib-the Latest First-Line Standard of Care Targeted Kinase Inhibitor for the Treatment of Advanced Renal Cell Carcinoma
    Lu, Taylor Y.
    Rampersaud, Edward N.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2014, 6 : 25 - 32
  • [10] Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma
    Vitale, Maria Giuseppa
    Nasso, Cecilia
    Oltrecolli, Marco
    Baldessari, Cinzia
    Fanelli, Martina
    Dominici, Massimo
    Sabbatini, Roberto
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (11) : 1183 - 1192
12345